Pall Corp. launched an expanded line of upstream and downstream capabilities, including new single-use technologies for biopharmaceutical manufacturing, at INTERPHEX 2014. With the recent acquisitions of the LifeSciences business of ATMI, Medistad Holding B.V. and SoloHill Engineering Inc., Pall strengthened its upstream capabilities and already-established portfolio of single-use technologies, the company said.
Some of the new technologies include:
- The AllegroTM STR 200 single-use bioreactor system for production-scale applications. It is available in working volumes up to 200L. The single-use stirred tank bioreactor features mixing and mass transfer characteristics for upflow or downflow operations with minimum shear.
- An expanded range of cubical and round single-use tanks for biopharmaceutical and pharmaceutical mixing applications. There are 64 tanks designed for use, from bench to commercial scale, featuring standard options including ASME-certified insulated jackets and load cells with displays.
- The LevPakTM system, which uses TK8 film, enables mixing, storage, shipping, remixing and dispensing of final biopharmaceutical and vaccine products in a single unit. It replaces traditional shipping methods, such as glass or plastic bottles, and removes the need for additional process steps once a customer receives product, as it is ready to be mixed in situ.
For more information, visit www.pall.com.
